Over the past decade, there has been an evolution of genetic testing and discovery of disease mechanisms that have enabled a new era of experimental and approved gene targeted therapy for genetic neuromuscular diseases. Therapeutic strategies have included protein replacement, gene replacement, RNA interference, antisense oligonucleotides, gene editing and small molecule approaches. There is a […] Read More
This session will review therapeutic advances in the treatment of patients with early-symptomatic Alzheimer disease and related dementias, discussing real-world experience with emergent therapeutics for early-symptomatic Alzheimer disease (i.e., anti-amyloid therapies), promising developments relevant to the treatment of Lewy body disease (i.e., insights and results from the SHIMMER Trial of CT1812), and therapeutics in development […] Read More
Neurological disorders represent a significant and growing burden in global health, with disparities in access to care, specialized training, and healthcare infrastructure disproportionately affecting low-and middle-income countries (LMICs). Despite these challenges, leaders in global neurology have successfully developed and expanded models of care that integrate neurology into inpatient wards, intensive care units (ICUs), and outpatient […] Read More
Psychiatric comorbidity and epilepsy have a bidirectional relationship, suggesting a common underlying pathophysiology that is not well understood. Further, psychiatric comorbidities are especially common in epilepsy and associated with numerous adverse outcomes, yet underrecognized and undertreated in clinical practice. Thus, translational research is needed in this area, spanning the entire translational spectrum from basic science […] Read More
This session is particularly timely, as it presents groundbreaking insights and advancements in the management of complex neurological conditions. This year’s highlights—including spinocerebellar ataxias (SCAs), dystonic cerebral palsy, and deep brain stimulation for Parkinson’s disease (PD)—address significant challenges in clinical practice, necessitating innovative therapeutic strategies. Dr. Sheng-Han Kuo from Columbia University will explore the transformative […] Read More
In the past decade, there has been a proliferation of clinical and translational studies using immunomodulatory agents or cells against adult glioblastoma, a deadly malignancy in the brain. Although initial trials using off-the-shelve checkpoint inhibitors did not improve progression-free survival or overall survival in this population, newer strategies like patient derived personalized cellular immunotherapy, neoantigen […] Read More
This session will feature invited presentations on sleep and epilepsy, REM Sleep Behavior Disorder (RBD), and Circadian Medicine. Sleep can affect seizures, and sleep deprivation is a common trigger of seizures. Some epilepsy syndromes are highly related to sleep. RBD is considered a prodromal stage of evolving synuclein-specific neurodegenerative disorders and understanding its progression biomarkers […] Read More
The session will discuss the evidence from the current clinical and translational research on the impact of sleep and circadian biology on traumatic brain injury and/or critical neurologic injuries, including how these injuries can adversely affect patient’s sleep in the short and long term. This session will review the physiologic role of sleep in brain […] Read More
This session will review updates in autoimmune neurologic disorders of the central nervous system and multiple sclerosis. It will focus on fluid based biomarkers (e.g., serum neurofilament light chain and glial fibrillary acidic protein) in MS and autoimmune neurologic disorders including their prognostic value and how they should be incorporated into clinical practice. Moreover, their […] Read More
This session aims to provide important updates of interest to members of the American Neurological Association attending the Annual Meeting. Specifically, we will include a cross-section of contemporary and cutting-edge topics in stroke and brain health. The areas presented will include genetic and environmental risk factors for intracerebral hemorrhage, GLP-1 agonists: a promising drug in […] Read More